New Multi-omic Blood Test Detects 61.5 Percent of Endometriosis Cases Missed by Imaging: Study Finds
A novel multi-omic blood test integrating biomarkers with machine learning identifies 61.5% of endometriosis cases previously missed by standard imaging, with exceptional diagnostic precision, a recent study published in The Journal of Minimally Invasive Gynecology in February 2026 has shown.
Endometriosis affects up to 10% of reproductive-age women, yet diagnosis is frequently delayed by nearly a decade due to the reliance on invasive laparoscopy and the inconsistency of previously researched microRNAs (miRNAs), which were often hindered by biological variability and methodological differences. To resolve this clinical gap, Dr. Farideh Z. Bischoff and the team at Heranova Lifesciences conducted an investigation aimed at developing a non-invasive, blood-based diagnostic tool that utilizes machine learning to accurately detect the disease across different menstrual phases.
Therefore, the multi-center case-control study included 298 symptomatic women whose condition was verified by histopathology, utilizing a random forest machine learning model to analyze three miRNAs, three proteins, and progesterone levels. The protocol excluded control subjects with known adenomyosis and focused on the primary endpoint of achieving a high rule-in specificity to reduce unnecessary surgical interventions while maintaining diagnostic accuracy throughout the menstrual cycle.
Key Clinical Findings of the Study Include:
Exceptional Diagnostic Performance: The investigation demonstrated a high AUC of 0.944, characterized by a sensitivity of 0.80 and a robust specificity of 0.975 in the independent validation cohort.
Clinical Complementarity: The study identified 61.5% of histologically confirmed endometriosis cases that had been incorrectly categorized as negative by transvaginal ultrasound or magnetic resonance imaging (MRI).
Cycle-Independent Reliability: The research confirmed consistent diagnostic results regardless of phase, with the AUC reaching 0.935 during the proliferative stage and 0.993 during the secretory stage.
Sophisticated Model Integration: The study effectively combined molecular biomarkers with patient factors such as age and body mass index (BMI) to maximize the precision of disease classification.
The results suggest that a multi-omic approach, which produced an AUC of 0.944 and a 0.975 specificity, serves as a highly reliable and minimally invasive diagnostic aid for symptomatic women. This integration of multiple biological axes provides the robustness necessary to guide timely clinical interventions.
Thus the study concludes that clinicians may find this multi-omic blood test useful as a supplementary triage tool to facilitate earlier detection and more efficient patient management.
The study was limited by its modest validation sample size and the need for future prospective research in larger, more diverse populations to confirm these diagnostic outcomes in early-stage disease.
Reference
Wing Hing Wong, Yanqin Yu, Yao Hu, et al. Non-invasive blood-based detection of endometriosis can improve standard-of-care by facilitating early diagnosis and clinical management among symptomatic women. The Journal of Minimally Invasive Gynecology (2026).
